

## Kaiser Permanente Research Brief

# Diabetes

**This brief summarizes the contributions of Kaiser Permanente Research on the topic of diabetes since 2012, including type 1, type 2, and gestational diabetes.**

The Centers for Disease Control and Prevention estimates that 37.3 million people in the United States – more than 11% of the population – are living with diabetes, and an additional 38% of U.S. adults have prediabetes.<sup>1</sup> The prevalence of both diabetes (29%) and prediabetes (49%) is higher among adults age 65 or older than among those under age 65.

Diabetes is an active area of study for Kaiser Permanente Research. Scientists across the organization have used our rich, comprehensive, longitudinal data to advance understanding of risk, improve patient outcomes, and translate research findings into policy and practice. We have published more than 1,100 articles related to diabetes since 2012; together, they have been cited approximately 41,000 times.<sup>2</sup>


These articles are the product of observational studies, randomized controlled trials, meta-analyses, and other studies led by Kaiser Permanente scientists. The unique environment – which includes our fully integrated care and coverage model – in which our research scientists, clinicians, medical groups, and health plan leaders collaborate enables us to contribute generalizable knowledge on diabetes and many other research topics.

## Understanding Risk

### Who is at risk for developing diabetes?

In adults, we have studied who is most at risk for developing type 2 diabetes. A selection of the risk factors for diabetes that Kaiser Permanente studies have assessed include obesity,<sup>3,4</sup> fasting plasma glucose levels,<sup>5,6</sup> levels of circulating acylcarnitine metabolites,<sup>7</sup> genetic factors,<sup>8,9</sup> use of antidepressant

### Kaiser Permanente publications related to diabetes since 2012



Source: Kaiser Permanente Publications Library and Scite metrics, as of August 24, 2023.

This brief summarizes a selection of the publications contained within the Kaiser Permanente Publications Library, which indexes journal articles and other publications authored by individuals affiliated with Kaiser Permanente. The work described in this brief originated from across Kaiser Permanente's 8 regions and was supported by a wide range of funding sources including internal research support as well as both governmental and nongovernmental extramural funding.

medications,<sup>10</sup> and use of antihypertensive medication combination therapy.<sup>11</sup> Recent work has also suggested that breast cancer survivors may have an elevated risk of diabetes.<sup>12</sup> People whose spouses or partners are diagnosed with diabetes have been found to be at greater risk of diabetes themselves.<sup>13</sup> Factors that reduce diabetes risk, such as weight loss,<sup>14</sup> dietary quality,<sup>15;16</sup> social support,<sup>17</sup> and successful treatment of other health conditions,<sup>18;19</sup> have also been the subject of Kaiser Permanente research.

Gestational diabetes is an important health concern for pregnant women. Factors that increase the risk of developing gestational diabetes<sup>20;21</sup> have been studied widely, as has the risk of recurrence of gestational diabetes in subsequent pregnancies,<sup>22</sup> and the risk of sustained glucose dysregulation and type 2 diabetes after pregnancy among women with a history of gestational diabetes.<sup>23-26</sup>

Among youth, Kaiser Permanente researchers have found significant increases over time in both incidence and prevalence of type 1 and type 2 diabetes,<sup>27-30</sup> with people of color impacted more heavily.<sup>31;32</sup> A substantial volume of work has addressed diabetes risk factors among youth, including dietary, physical activity, and weight loss factors,<sup>33-38</sup> as well as risks linked to maternal gestational diabetes status and other perinatal and neonatal factors.<sup>39;40</sup>

### What other health risks do people with diabetes face?

People with diabetes face added health risks, including higher mortality<sup>41;42</sup> and risks related to the use of medications for treating diabetes. Kaiser Permanente research scientists have authored studies evaluating the risks of complications of diabetes (for example, nephropathy, neuropathy, or retinopathy) and common comorbidities (for example, hypertension or arterial stiffness),<sup>24;43-47</sup> the risk of developing various cancers,<sup>48-50</sup> the risk of bone fractures,<sup>51-53</sup> and other adverse outcomes.<sup>52</sup> In children with type 1 or type 2 diabetes, these complications and comorbidities often appear as early as adolescence and early adulthood, with a greater burden among those with type 2

diabetes.<sup>54-56</sup> Studies have also demonstrated an increase in risks of cognitive decline and dementia for people with diabetes who have experienced hypoglycemic episodes, those with poor glucose control, and those with comorbid depression.<sup>57-63</sup> Kaiser Permanente research has also investigated risks related to chronic conditions that are often comorbid with diabetes, such as pulmonary, kidney, and cardiovascular diseases.<sup>56;64-67</sup>

Bariatric surgery is an increasingly common risk-mitigation strategy for people with diabetes and obesity. Studies have shown that – particularly for people with less severe obesity – bariatric surgery can result in diabetes remission and a host of related benefits,<sup>68-80</sup> including improved

### Diabetes remission for patients with type 2 diabetes who received bariatric surgery versus non-surgical approaches

#### Adults with severe obesity and diabetes

**1,395**

Bariatric surgeries

**62,322**

Non-surgical approaches

#### Diabetes remission at 2 years

**73.7%**

95% CI: 70.7-76.5

**6.9%**

95% CI: 6.9-7.1

#### Hazard ratios for secondary outcomes

##### Relapse

Lower for surgery group



**0.19**

95% CI: 0.15-0.23

##### Death

No difference between groups



**0.54**

95% CI: 0.22-1.30

Arterburn, D., et al., *Comparative effectiveness of bariatric surgery vs. nonsurgical treatment of type 2 diabetes among severely obese adults*. *Obes Res Clin Pract*, 2013. 7(4): p. e258-68

## There are 3 components of effective blood glucose control for diabetes

### Lifestyle management

- Diet
- Physical activity



### Self-monitoring of glucose levels

### Medication

- Addressing adherence
- Intensification if needed



life expectancy.<sup>81;82</sup> Even for people who experience a relapse of diabetes after a period of remission, the remission has been linked to longer-term health benefits, such as reduced risk of microvascular complications of diabetes.<sup>70</sup>

Also important are the risks for babies born to women who experience gestational diabetes, as well as those with type 1 or type 2 diabetes. Among these risks are fetal and neonatal macrosomia,<sup>83;84</sup> impaired glucose tolerance,<sup>85</sup> hypoglycemia,<sup>84</sup> childhood obesity,<sup>86-89</sup> and development of autism<sup>90;91</sup> and ADHD.<sup>92</sup>

## Improving Patient Outcomes

### What strategies are effective in preventing diabetes?

For people at risk of type 2 diabetes, making a timely diagnosis of prediabetes creates an opportunity to encourage lifestyle changes that can reduce the risk of developing diabetes.<sup>3;93-95</sup> Kaiser Permanente researchers have studied the performance of various approaches to detecting prediabetes<sup>5;94;96</sup> and the rate of progression from pre-diabetic states to diabetes.<sup>3;97</sup>

Approaches to prevention or risk reduction studied by Kaiser Permanente researchers include increasing knowledge about diabetes among

youth;<sup>98</sup> lifestyle interventions (including vitamin D supplementation) for high-risk adults;<sup>99-103</sup> targeted interventions in spouses, partners, and other family members of patients with diabetes;<sup>104</sup> and personalized genetic-risk counseling.<sup>105</sup>

### How does early identification of diabetes affect outcomes?

Early diagnosis of diabetes relies on screening of people at risk.<sup>106</sup> Early recognition of type 1 and type 2 diabetes can confer substantial treatment and outcome benefits. For example, people who are diagnosed early can enter treatment before consequences of uncontrolled diabetes occur, such as diabetic ketoacidosis.<sup>107-109</sup>

### What are the key factors in effective treatment of people with diabetes?

**Glucose Control.** For people with diabetes, glucose control – through self-management activities including lifestyle adaptations,<sup>110</sup> self-monitoring of blood glucose, and medication adherence – is essential to effective treatment.<sup>111;112</sup> Our research has emphasized the value of addressing food insecurity and other unmet basic needs among patients with diabetes, as these needs have been linked to poor diabetes control and higher rates of hospitalizations and emergency room visits.<sup>113;114</sup> Timely initiation of glucose-lowering pharmacotherapy is key, and Kaiser Permanente scientists have found racial disparities in rates of treatment initiation for patients with lower glycated hemoglobin, or HbA1c, values.<sup>115</sup> Diabetes care guidelines suggest an escalating medication treatment strategy for people with type 2 diabetes based on glucose control and responsiveness to medications. However, discontinuation of treatment is common,<sup>116</sup> and medications are not always escalated as recommended, even when glycemic control is inadequate,<sup>117;118</sup> in part because of barriers to insulin initiation,<sup>118-120</sup> medication costs,<sup>121</sup> and the complexity of the medication regimen.<sup>122;123</sup> As such, it is not unusual for patients with type 2 diabetes to experience extended periods of suboptimal glucose control.<sup>124</sup> Use of common glucose-lowering medications in the management of gestational diabetes is controversial, as their safety in pregnant women

has not been clearly established,<sup>125</sup> and the use of insulin during pregnancy is frequently a negative, anxiety-provoking experience.<sup>126</sup> In young adults with earlier onset of diabetes, glucose control may be adversely affected by factors such as support from family members,<sup>127</sup> or the transition between pediatric and adult primary care.<sup>128-130</sup>

For most adults with diabetes, the goal of treatment is to maintain a hemoglobin A1c (HbA1c) of less than 7%. Kaiser Permanente studies have compared the effectiveness of alternative medication regimens<sup>131-134</sup> and glucose control targets. In particular, researchers have recently studied the appropriateness of low glycemic targets for older adults and concluded that relaxing glucose control targets (for example, up to HbA1c of 7.5%) for older adults can avoid hypoglycemic events and other adverse outcomes, with few negative consequences.<sup>135;136</sup> Kaiser Permanente studies have suggested opportunities for reducing prescribing of higher-risk treatments in older patients.<sup>137;138</sup> Other work conducted by our scientists has found that glycemic control among Latino patients with limited English proficiency can be improved by matching them with bilingual primary care physicians.<sup>139</sup> Finally, our researchers have explored the efficacy of continuous glucose monitoring in insulin-treated patients with type 2 diabetes.<sup>140;141</sup> Such real-world studies conducted within our large membership provide valuable insights that complement clinical trials, which frequently exclude older adults and people with comorbidities.

### **Screening for Complications of Diabetes.**

Appropriate screening for serious complications of diabetes is an essential component of effective treatment. Recommended processes of care include eye exams, foot exams, and influenza immunizations. Kaiser Permanente studies have measured the impact of insurance continuity or coverage type on receiving recommended preventive care.<sup>142-144</sup> Even among insured people, gaps in recommended care processes are common.<sup>145;146</sup>

**Managing Comorbid Conditions.** People with diabetes and multiple comorbid conditions face added challenges and risks. One of these is polypharmacy, or the concurrent use of multiple prescription medications. Kaiser Permanente research has demonstrated that medication burden increases substantially for adult patients newly diagnosed with diabetes.<sup>147</sup> Polypharmacy is linked with decreased medication adherence.<sup>148</sup>

In addition, chronic and acute conditions can be more difficult to treat in the context of diabetes than for people without diabetes. For example, surgical care of patients with diabetes and surgical treatment of diabetic foot infections are complicated by microvascular diseases that inhibit wound healing.<sup>149;150</sup> Studies have also demonstrated that people with comorbid diabetes and hypertension, hyperlipidemia, hyperglycemia, and chronic kidney disease often experience both treatment nonadherence and lack of appropriate treatment intensification for these comorbidities, leading to worse outcomes.<sup>151-153</sup>

## **Translating Research Findings Into Policy and Practice**

Kaiser Permanente is a learning health care organization that works to systematically use research to inform and improve practice both within Kaiser Permanente and more broadly. Within Kaiser Permanente, research, clinical, and operational partners have tested a range of interventions to prevent diabetes or improve diabetes outcomes. These have included strategies such as education, wellness, and behavior change programs focused on exercise, diet, and medication adherence;<sup>154-157</sup> collaborative care programs for patients with diabetes and comorbid behavioral health problems;<sup>158-162</sup> pharmacist-led diabetes management;<sup>163</sup> workplace screening and wellness programs;<sup>157;164</sup> a virtualized reading center for diabetic retinopathy screening;<sup>165</sup> mail-order pharmacy delivery for diabetes medications;<sup>166;167</sup> and educational interventions specifically for women with gestational diabetes<sup>168</sup> and youth.<sup>98</sup> Within Kaiser Permanente, studies have also evaluated

the role of electronic health records (and other data assets) in improving quality of diabetes care, identifying diabetes medication nonadherence, and recognizing prediabetes and other outcomes, including diabetes complications.<sup>96;169-180</sup>

Disease management programs, often offered by third-party vendors, are increasingly popular in the United States, and are widely used by state Medicaid programs and others. Our studies that assess online and telephonic disease management or coaching programs have found that they can be effective but are not uniformly so.<sup>156;181</sup> Furthermore, these programs have been shown to face challenges related to low uptake among eligible individuals who might benefit.<sup>182</sup> Researchers have also found that linking these efforts back to primary care is challenging, even in an integrated care setting with a mature electronic health record system.<sup>183</sup>

Kaiser Permanente research contributes to policy and practice change within our own care delivery model and has advanced the national knowledge of diabetes. To date, Kaiser Permanente authors have been cited nearly 250 times within recent consensus statements and clinical practice guidelines published by a wide range of entities, including the American Diabetes Association, American Heart Association, and the American Geriatrics Association, among others. In addition, Kaiser Permanente research and clinician scientists have directly contributed as authors of practice guidelines and systematic reviews. These include reviews published by the U.S. Preventive Services Task Force,<sup>184-186</sup> and the American Association of Clinical Endocrinologists and American College of Endocrinology's consensus statements on the type 2 diabetes management algorithm.<sup>187-190</sup> Finally, our scientists have co-authored a report on research gaps in gestational diabetes for the National Institute of Diabetes and Digestive and Kidney Diseases.<sup>191</sup>

Each of Kaiser Permanente's regional research centers participates in the Health Care Systems Research Network, a national research network that aims to improve individual and population health through research.<sup>192</sup> The SUPREME-DM study, focused on diabetes and led by a Kaiser Permanente researcher, is one of HCSRN's cornerstone projects. Kaiser Permanente researchers have led or collaborated on many notable studies and trials related to diabetes epidemiology, prevention, risk factors, and treatment. Our researchers are part of a team recently awarded a \$5.6 million grant by the Patient-Centered Outcomes Research Institute, studying the cardiovascular health effects of second-line medications for type 2 diabetes.<sup>193</sup> Kaiser Permanente scientists are also involved in the Hyperglycemia and Adverse Pregnancy Outcome - Cardiovascular Health (HAPO-CVH) study, which will investigate the cardiovascular wellness of children born to mothers who experienced gestational diabetes during the original HAPO study, and the Assessing the Burden of Diabetes by Type in Children, Adolescents, and Young Adults (DiCAYA) Network, a CDC-sponsored project aimed at increasing the effectiveness of diabetes surveillance using electronic health records.<sup>194</sup>

Kaiser Permanente's 185 research scientists and 1,530 support staff members are based at 9 research centers. There are currently 2,355 studies underway, including clinical trials. Since 2012 our research scientists have published more than 19,000 articles in peer-reviewed journals. Kaiser Permanente currently serves more than 12.6 million members in 8 states and the District of Columbia.

This brief was written by Nicholas P. Emptage, Anna C. Davis, and Elizabeth A. McGlynn. It is available online at [about.kp.org/our-story/health-research/research-briefs](https://about.kp.org/our-story/health-research/research-briefs). The authors wish to thank the following researchers for their contributions to the development of this brief: Kristi Reynolds, Julie A. Schmittiel, and John F. Steiner.



## References

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA: Author; 2022.
2. KPPL Search, conducted on August 24, 2023: (dc.title:diabet\* OR dc.title:prediabet\* OR dc.title:prediabet\* OR dc.title:"SUPREME-DM" OR dc.subject.mesh:"diabetes mellitus" OR dc.subject.mesh:"diabetes complications" OR dc.subject.mesh:"diabetes, gestational" OR dc.subject.mesh:"prediabetic state") AND dc.type:"Journal Article". Date: 2012 to 2023.
3. Glauber H, Vollmer WM, Nichols GA. A Simple Model for Predicting Two-Year Risk of Diabetes Development in Individuals with Prediabetes. *Perm J*. 2018;22:17-050.
4. Luo J, Hendryx M, Laddu D, et al. Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. *Diabetes Care*. 2019;42(1):126-133.
5. Hsia DS, Rasouli N, Pittas AG, et al. Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. *J Clin Endocrinol Metab*. 2020;105(3):e130-e138.
6. Sternfeld B, Gabriel KP, Jiang SF, et al. Risk Estimates for Diabetes and Hypertension with Different Physical Activity Methods. *Med Sci Sports Exerc*. 2019;51(12):2498-2505.
7. Batchuluun B, Al Rijjal D, Prentice KJ, et al. Elevated Medium Chain-Acylcarnitines are Associated with Gestational Diabetes, and Early Progression to Type-2 Diabetes, and Induce Pancreatic  $\beta$ -Cell Dysfunction. *Diabetes*. 2018;67(5):885-897.
8. Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet*. 2021;53(7):962-971.
9. Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet*. 2022;54(5):560-572.
10. de Groot M, Marrero D, Mele L, et al. Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. *Psychosom Med*. 2018;80(2):167-173.
11. Cooper-DeHoff RM, Bird ST, Nichols GA, et al. Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. *J Am Heart Assoc*. 2013;2(3):e000125.
12. Kwan ML, Cheng RK, Iribarren C, et al. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. *J Clin Oncol*. 2022;40(15):1635-1646.
13. Cunningham SA, Adams SR, Schmittiel JA, Ali MK. Incidence of diabetes after a partner's diagnosis. *Prev Med*. 2017;105:52-57.
14. Koebnick C, Smith N, Huang K, et al. The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California. *Ann Epidemiol*. 2012;22(9):609-616.
15. Choi Y, Larson N, Gallaher DD, et al. A Shift Toward a Plant-Centered Diet From Young to Middle Adulthood and Subsequent Risk of Type 2 Diabetes and Weight Gain: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Diabetes Care*. 2020;43(11):2796-2803.
16. Li J, Glenn AJ, Yang Q, et al. Dietary Protein Sources, Mediating Biomarkers, and Incidence of Type 2 Diabetes: Findings From the Women's Health Initiative and the U.K. Biobank. *Diabetes Care*. 2022;45(8):1742-1753.
17. Hendryx M, Nicholson W, Manson JE, et al. Social Relationships and Risk of Type 2 Diabetes Among Postmenopausal Women. *J Gerontol B Psychol Sci Soc Sci*. 2020;75(7):1597-1608.
18. Li J, Gordon SC, Rupp LB, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. *Aliment Pharmacol Ther*. 2019;49(5):599-608.
19. Li J, Gordon SC, Rupp LB, et al. Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C. *Liver Int*. 2019;39(6):1027-1032.
20. Zhu Y, Hedderson MM, Quesenberry CP, et al. Central Obesity Increases the Risk of Gestational Diabetes Partially Through Increasing Insulin Resistance. *Obesity (Silver Spring)*. 2019;27(1):152-160.
21. Zhu Y, Tsai MY, Sun Q, et al. A prospective and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes. *Am J Clin Nutr*. 2018;107(6):1017-1026.
22. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. *Nat Rev Endocrinol*. 2012;8(11):639-649.
23. Ehrlich SF, Hedderson MM, Quesenberry CP, et al. Post-partum weight loss and glucose metabolism in women with gestational diabetes: the DEBI Study. *Diabet Med*. 2014;31(7):862-867.
24. Lowe WL, Scholtens DM, Lowe LP, et al. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. *JAMA*. 2018;320(10):1005-1016.
25. Lo JC, Yang J, Gunderson EP, et al. Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome. *J Diabetes Res*. 2017;2017:5250162.
26. Lai M, Liu Y, Ronnett GV, et al. Amino acid and lipid metabolism in post-gestational diabetes and progression to type 2 diabetes: A metabolic profiling study. *PLoS Med*. 2020;17(5):e1003112.

27. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA*. 2014;311(17):1778-1786.
28. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. *N Engl J Med*. 2017;376(15):1419-1429.
29. Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths - Selected Counties and Indian Reservations, United States, 2002-2015. *MMWR Morb Mortal Wkly Rep*. 2020;69(6):161-165.
30. Lawrence JM, Divers J, Isom S, et al. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. *JAMA*. 2021;326(8):717-727.
31. Kahkoska AR, Shay CM, Crandell J, et al. Association of Race and Ethnicity With Glycemic Control and Hemoglobin A1c Levels in Youth With Type 1 Diabetes. *JAMA Netw Open*. 2018;1(5):e181851.
32. Zhu Y, Sidell MA, Arterburn D, et al. Racial/Ethnic Disparities in the Prevalence of Diabetes and Prediabetes by BMI: Patient Outcomes Research To Advance Learning (PORTAL) Multisite Cohort of Adults in the U.S. *Diabetes Care*. 2019;42(12):2211-2219.
33. Berkowitz SA, Karter AJ, Corbie-Smith G, et al. Food Insecurity, Food "Deserts," and Glycemic Control in Patients With Diabetes: A Longitudinal Analysis. *Diabetes Care*. 2018;41(6):1188-1195.
34. Couch SC, Crandell JL, Shah AS, et al. Fructose intake and cardiovascular risk factors in youth with type 1 diabetes: SEARCH for diabetes in youth study. *Diabetes Res Clin Pract*. 2013;100(2):265-271.
35. Mendoza JA, Haaland W, D'Agostino RB, et al. Food insecurity is associated with high risk glycemic control and higher health care utilization among youth and young adults with type 1 diabetes. *Diabetes Res Clin Pract*. 2018;138:128-137.
36. Nip ASY, Reboussin BA, Dabelea D, et al. Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2 Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2019;42(5):859-866.
37. Zhang YT, Mujahid MS, Laraia BA, et al. Association Between Neighborhood Supermarket Presence and Glycated Hemoglobin Levels Among Patients With Type 2 Diabetes Mellitus. *Am J Epidemiol*. 2017;185(12):1297-1303.
38. Zhong VW, Lamichhane AP, Crandell JL, et al. Association of adherence to a Mediterranean diet with glycemic control and cardiovascular risk factors in youth with type 1 diabetes: the SEARCH Nutrition Ancillary Study. *Eur J Clin Nutr*. 2016;70(7):802-807.
39. Gunderson EP, Greenspan LC, Faith MS, et al. Breastfeeding and growth during infancy among offspring of mothers with gestational diabetes mellitus: a prospective cohort study. *Pediatr Obes*. 2018;13(8):492-504.
40. Khan SR, Mohan H, Liu Y, et al. The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes. *Diabetologia*. 2019;62(4):687-703.
41. Lawrence JM, Reynolds K, Saydah SH, et al. Demographic Correlates of Short-Term Mortality Among Youth and Young Adults With Youth-Onset Diabetes Diagnosed From 2002 to 2015: The SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2021;44(12):2691-2698.
42. Reynolds K, Saydah SH, Isom S, et al. Mortality in youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth study. *J Diabetes Complications*. 2018;32(6):545-549.
43. Dehmer EW, Phadnis MA, Gunderson EP, et al. Association Between Gestational Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Kidney Dis*. 2018;71(1):112-122.
44. Karter AJ, Lipska KJ, O'Connor PJ, et al. High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. *J Diabetes Complicat*. 2017;31(5):869-873.
45. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes: The Diabetes and Aging Study. *Diabetes Care*. 2013;36(11):3535-3542.
46. An J, Nichols GA, Qian L, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. *BMJ Open Diabetes Res Care*. 2021;9(1):e001847.
47. Jensen ET, Rigdon J, Rezaei KA, et al. Prevalence, Progression, and Modifiable Risk Factors for Diabetic Retinopathy in Youth and Young Adults With Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2023;46(6):1252-1260.
48. Habel LA, Danforth KN, Quesenberry CP, et al. Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes. *Diabetes Care*. 2013;36(12):3953-3960.
49. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. *JAMA*. 2015;314(3):265-277.
50. Huang BZ, Pandol SJ, Jeon CY, et al. New-onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population. *Clin Gastroenterol Hepatol*. 2020;18(8):1812-1821.e1817.

51. Isakova T, Craven TE, Scialla JJ, et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. *Bone*. 2015;78:23-27.
52. Kabue S, Liu V, Dyer W, et al. Identifying Common Predictors of Multiple Adverse Outcomes Among Elderly Adults With Type-2 Diabetes. *Med Care*. 2019;57(9):702-709.
53. Schwartz AV, Ewing SK, Porzig AM, et al. Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women. *Front Endocrinol (Lausanne)*. 2013;4:62.
54. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA*. 2017;317(8):825-835.
55. Sauder KA, Stafford JM, Mayer-Davis EJ, et al. Co-occurrence of early diabetes-related complications in adolescents and young adults with type 1 diabetes: an observational cohort study. *Lancet Child Adolesc Health*. 2019;3(1):35-43.
56. Kim G, Divers J, Fino NF, et al. Trends in Prevalence of Cardiovascular Risk Factors from 2002-2012 among Youth Early in the Course of Type 1 and Type 2 Diabetes. The SEARCH for Diabetes in Youth Study. *Pediatr Diabetes*. 2019;20(6):693-701.
57. Exalto LG, Biessels GJ, Karter AJ, et al. Severe Diabetic Retinal Disease and Dementia Risk in Type 2 Diabetes. *J Alzheimers Dis*. 2014;42 Suppl 3:S109-117.
58. Gilsanz P, Schnaider Beerli M, Karter AJ, et al. Depression in type 1 diabetes and risk of dementia. *Aging Ment Health*. 2019;23(7):880-886.
59. Katon W, Lyles CR, Parker MM, et al. Association of Depression With Increased Risk of Dementia in Patients With Type 2 Diabetes: The Diabetes and Aging Study. *Arch Gen Psychiatry*. 2012;69(4):410-417.
60. Lacy ME, Gilsanz P, Karter AJ, et al. Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. *Diabetes Care*. 2018;41(11):2339-2345.
61. Lacy ME, Gilsanz P, Eng C, et al. Severe Hypoglycemia and Cognitive Function in Older Adults With Type 1 Diabetes: The Study of Longevity in Diabetes (SOLID). *Diabetes Care*. 2020;43(3):541-548.
62. Lacy ME, Moran C, Gilsanz P, et al. Comparison of cognitive function in older adults with type 1 diabetes, type 2 diabetes, and no diabetes: results from the Study of Longevity in Diabetes (SOLID). *BMJ Open Diabetes Res Care*. 2022;10(2):e002557.
63. Whitmer RA, Gilsanz P, Quesenberry CP, et al. Association of Type 1 Diabetes and Hypoglycemic and Hyperglycemic Events and Risk of Dementia. *Neurology*. 2021;97(3):e275-e283.
64. Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. *J Am Coll Cardiol*. 2017;70(11):1325-1335.
65. Nichols GA, Déruaz-Luyet A, Hauske SJ, Brodovicz KG. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. *J Diabetes Complicat*. 2018;32(3):291-297.
66. Shah AS, Maahs DM, Stafford JM, et al. Predictors of Dyslipidemia Over Time in Youth With Type 1 Diabetes: For the SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2017;40(4):607-613.
67. Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States Population, 2009-2014. *Clin J Am Soc Nephrol*. 2017;12(12):1984-1990.
68. Arterburn D, Bogart A, Coleman KJ, et al. Comparative effectiveness of bariatric surgery vs. nonsurgical treatment of type 2 diabetes among severely obese adults. *Obes Res Clin Pract*. 2013;7(4):e258-268.
69. Arterburn DE, Bogart A, Sherwood NE, et al. A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass. *Obes Surg*. 2013;23(1):93-102.
70. Coleman KJ, Haneuse S, Johnson E, et al. Long-Term Microvascular Disease Outcomes in Patients With Type 2 Diabetes After Bariatric Surgery: Evidence for the Legacy Effect of Surgery. *Diabetes Care*. 2016;39(8):1400-1407.
71. Fisher DP, Johnson E, Haneuse S, et al. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. *JAMA*. 2018;320(15):1570-1582.
72. McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. *JAMA Surg*. 2020;155(5):e200087.
73. O'Brien R, Johnson E, Haneuse S, et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. *Ann Intern Med*. 2018;169(5):300-310.
74. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. *JAMA*. 2020;324(9):879-887.
75. Barthold D, Brouwer E, Barton LJ, et al. Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remission. *Diabetes Care*. 2022;45(1):92-99.
76. Aminian A, Zajichek A, Arterburn DE, et al. Predicting 10-Year Risk of End-Organ Complications of Type 2 Diabetes With and Without Metabolic Surgery: A Machine Learning Approach. *Diabetes Care*. 2020;43(4):852-859.



77. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). *Diabetes Care*. 2022;45(7):1574-1583.
78. Coleman KJ, Basu A, Barton LJ, et al. Remission and Relapse of Dyslipidemia After Vertical Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass in a Racially and Ethnically Diverse Population. *JAMA Netw Open*. 2022;5(9):e2233843.
79. Reynolds K, Barton LJ, Basu A, et al. Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study. *Hypertension*. 2021;78(4):1116-1125.
80. Coleman KJ, Wellman R, Fitzpatrick SL, et al. Comparative Safety and Effectiveness of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy for Weight Loss and Type 2 Diabetes Across Race and Ethnicity in the PCORnet Bariatric Study Cohort. *JAMA Surg*. 2022;157(10):897-906.
81. Schauer DP, Arterburn DE, Livingston EH, et al. Impact of bariatric surgery on life expectancy in severely obese patients with diabetes: a decision analysis. *Ann Surg*. 2015;261(5):914-919.
82. Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study). *Diabetes Care*. 2019;42(3):416-426.
83. Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. *Diabetes Care*. 2013;36(1):56-62.
84. Sacks DA, Black MH, Li X, et al. Adverse Pregnancy Outcomes Using The International Association of the Diabetes and Pregnancy Study Groups Criteria: Glycemic Thresholds and Associated Risks. *Obstet Gynecol*. 2015;126(1):67-73.
85. Lowe WL, Scholtens DM, Kuang A, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes and Childhood Glucose Metabolism. *Diabetes Care*. 2019;42(3):372-380.
86. Ehrlich SF, Rosas LG, Ferrara A, et al. Pregnancy Glucose Levels in Women without Diabetes or Gestational Diabetes and Childhood Cardiometabolic Risk at 7 Years of Age. *J Pediatr*. 2012;161(6):1016-1021.
87. Hillier TA, Pedula KL, Vesco KK, et al. Impact of Maternal Glucose and Gestational Weight Gain on Child Obesity over the First Decade of Life in Normal Birth Weight Infants. *Matern Child Health J*. 2016;20(8):1559-1568.
88. Li S, Zhu Y, Yeung E, et al. Offspring risk of obesity in childhood, adolescence and adulthood in relation to gestational diabetes mellitus: a sex-specific association. *Int J Epidemiol*. 2017;46(5):1533-1541.
89. Page KA, Luo S, Wang X, et al. Children Exposed to Maternal Obesity or Gestational Diabetes Mellitus During Early Fetal Development Have Hypothalamic Alterations That Predict Future Weight Gain. *Diabetes Care*. 2019;42(8):1473-1480.
90. Xiang AH, Wang X, Martinez MP, et al. Maternal Type 1 Diabetes and Risk of Autism in Offspring. *JAMA*. 2018;320(1):89-91.
91. Xiang AH, Wang X, Martinez MP, et al. Association of maternal diabetes with autism in offspring. *JAMA*. 2015;313(14):1425-1434.
92. Xiang AH, Wang X, Martinez MP, et al. Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. *Diabetes Care*. 2018;41(12):2502-2508.
93. Kohli P, Knowles JW, Sarraju A, et al. Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). *Am J Cardiol*. 2016;118(9):1275-1281.
94. Marshall C, Adams S, Dyer W, Schmittiel J. Opportunities to Reduce Diabetes Risk in Women of Reproductive Age: Assessment and Treatment of Prediabetes within a Large Integrated Delivery System. *Womens Health Issues*. 2017;27(6):666-672.
95. Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. *Perm J*. 2014;18(3):88-93.
96. Schmittiel JA, Adams SR, Segal J, et al. Novel Use and Utility of Integrated Electronic Health Records to Assess Rates of Prediabetes Recognition and Treatment: Brief Report From an Integrated Electronic Health Records Pilot Study. *Diabetes Care*. 2014;37(2):565-568.
97. Rooney MR, Rawlings AM, Pankow JS, et al. Risk of Progression to Diabetes Among Older Adults With Prediabetes. *JAMA Intern Med*. 2021;181(4):511-519.
98. Schneider M, DeBar L, Calingo A, et al. The Effect of a Communications Campaign on Middle School Students' Nutrition and Physical Activity: Results of the HEALTHY Study. *J Health Commun*. 2013;18(6):649-667.
99. Fitzpatrick SL, Mayhew M, Catlin CL, et al. Evaluating the Implementation of Digital and In-Person Diabetes Prevention Program in a Large, Integrated Health System: Natural Experiment Study Design. *Perm J*. 2021;26(1):21-31.

100. Gibson B, Marcus RL, Staggers N, et al. Efficacy of a computerized simulation in promoting walking in individuals with diabetes. *J Med Internet Res*. 2012;14(3):e71.
101. Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. *N Engl J Med*. 2019;381(6):520-530.
102. Dawson-Hughes B, Staten MA, Knowler WC, et al. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study. *Diabetes Care*. 2020;43(12):2916-2922.
103. Gruß I, Firemark A, Papajorgji-Taylor D, Fitzpatrick SL. Challenges with implementing the Diabetes Prevention Program for Medicare beneficiaries in an integrated health system. *Am J Manag Care*. 2021;27(11):e400-e403.
104. Schmittziel JA, Cunningham SA, Adams SR, et al. Influence of a New Diabetes Diagnosis on the Health Behaviors of the Patient's Partner. *Ann Fam Med*. 2018;16(4):290-295.
105. Grant RW, O'Brien KE, Waxler JL, et al. Personalized Genetic Risk Counseling to Motivate Diabetes Prevention: A randomized trial. *Diabetes Care*. 2013;36(1):13-19.
106. Ngo-Metzger Q. Diabetes Screening: Different Thresholds for Different Racial/Ethnic Groups. *Ann Intern Med*. 2022;175(6):895-896.
107. Dabelea D, Rewers A, Stafford JM, et al. Trends in the Prevalence of Ketoacidosis at Diabetes Diagnosis: The SEARCH for Diabetes in Youth Study. *Pediatrics*. 2014;133(4):e938-945.
108. Jensen ET, Stafford JM, Saydah S, et al. Increase in Prevalence of Diabetic Ketoacidosis at Diagnosis Among Youth With Type 1 Diabetes: The SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2021;44(7):1573-1578.
109. Praveen PA, Hockett CW, Ong TC, et al. Diabetic ketoacidosis (DKA) at diagnosis among youth with type 1 and type 2 diabetes: results from SEARCH (US) and YDR (India) registries. *Pediatr Diabetes*. 2021;22(1):40-46.
110. Gadgil MD, Ehrlich SF, Zhu Y, et al. Dietary Quality and Glycemic Control Among Women with Gestational Diabetes Mellitus. *J Womens Health (Larchmt)*. 2019;28(2):178-184.
111. Schmittziel JA, Gopalan A, Lin MW, et al. Population Health Management for Diabetes: Health Care System-Level Approaches for Improving Quality and Addressing Disparities. *Curr Diab Rep*. 2017;17(5):31.
112. Ehrlich SF, Hedderson MM, Brown SD, et al. Moderate intensity sports and exercise is associated with glycaemic control in women with gestational diabetes. *Diabetes Metab*. 2017;43(5):416-423.
113. Schroeder EB, Zeng C, Sterrett AT, et al. The longitudinal relationship between food insecurity in older adults with diabetes and emergency department visits, hospitalizations, hemoglobin A1c, and medication adherence. *J Diabetes Complicat*. 2019;33(4):289-295.
114. Fitzpatrick SL, Banegas MP, Kimes TM, et al. Prevalence of Unmet Basic Needs and Association with Diabetes Control and Care Utilization Among Insured Persons with Diabetes. *Popul Health Manag*. 2021;24(4):463-469.
115. Gopalan A, Winn AN, Karter AJ, Laiteerapong N. Racial and Ethnic Differences in Medication Initiation Among Adults Newly Diagnosed with Type 2 Diabetes. *J Gen Intern Med*. 2022.
116. Reynolds K, An J, Wu J, et al. Treatment discontinuation of oral hypoglycemic agents and healthcare utilization among patients with diabetes. *J Diabetes Complicat*. 2016;30(8):1443-1451.
117. Pinto CA, Stafford JM, Wang T, et al. Changes in Diabetes Medication Regimens and Glycemic Control in Adolescents and Young Adults with Youth Onset Type 2 Diabetes: the SEARCH for Diabetes in Youth Study. *Pediatr Diabetes*. 2018;19(6):1065-1072.
118. Snyder LL, Stafford JM, Dabelea D, et al. Socio-economic, demographic and clinical correlates of poor glycaemic control within insulin regimens among children with Type 1 diabetes: the SEARCH for Diabetes in Youth study. *Diabet Med*. 2019;36(8):1028-1036.
119. Fernández A, Quan J, Moffet H, et al. Adherence to Newly Prescribed Diabetes Medications Among Insured Latino and White Patients With Diabetes. *JAMA Intern Med*. 2017;177(3):371-379.
120. Lipska KJ, Parker MM, Moffet HH, et al. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. *JAMA*. 2018;320(1):53-62.
121. Karter AJ, Parker MM, Solomon MD, et al. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). *Health Serv Res*. 2018;53(2):1227-1247.
122. Yeh A, Shah-Manek B, Lor KB. Medication Regimen Complexity and A1C Goal Attainment in Underserved Adults With Type 2 Diabetes. *Ann Pharmacother*. 2017;51(2):111-117.
123. Bennett WL, Aschmann HE, Puhon MA, et al. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type 2 diabetes in people with multiple chronic conditions. *J Clin Epidemiol*. 2019;113:92-100.
124. An J, Nichols GA, Qian L, et al. Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes. *J Diabetes Complicat*. 2020;34(8):107607.

125. Barbour LA, Scifres C, Valent AM, et al. A Cautionary Response to SMFM Statement: Pharmacological Treatment of Gestational Diabetes. *Am J Obstet Gynecol*. 2018;219(4):367.e361-367.e367.
126. Figueroa Gray M, Hsu C, Kiel L, Dublin S. "It's a Very Big Burden on Me": Women's Experiences Using Insulin for Gestational Diabetes. *Matern Child Health J*. 2017;21(8):1678-1685.
127. Gopalan A, Blatchins MA, Xu KK, et al. All in the Family: A Qualitative Study of the Early Experiences of Adults with Younger Onset Type 2 Diabetes. *J Am Board Fam Med*. 2022;35(2):341-351.
128. Agarwal S, Raymond JK, Isom S, et al. Transfer from paediatric to adult care for young adults with Type 2 diabetes: the SEARCH for Diabetes in Youth Study. *Diabet Med*. 2018;35(4):504-512.
129. Gopalan A, Mishra P, Alexeeff SE, et al. Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes. *Diabetes Care*. 2020;43(5):975-981.
130. Malik FS, Sauder KA, Isom S, et al. Trends in Glycemic Control Among Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. *Diabetes Care*. 2022;45(2):285-294.
131. Nichols GA, Kimes TM, Harp JB, et al. Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes. *Diabetes Care*. 2012;35(3):495-497.
132. Pihoker C, Badaru A, Anderson A, et al. Insulin Regimens and Clinical Outcomes in a Type 1 Diabetes Cohort: The SEARCH for Diabetes in Youth study. *Diabetes Care*. 2013;36(1):27-33.
133. Wei NJ, Wexler DJ, Nathan DM, Grant RW. Intensification of diabetes medication and risk for 30-day readmission. *Diabet Med*. 2013;30(2):e56-62.
134. Nathan DM, Lachin JM, Bebu I, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. *N Engl J Med*. 2022;387(12):1075-1088.
135. Lee EA, Gibbs NE, Martin J, et al. Improving Care in Older Patients with Diabetes: A Focus on Glycemic Control. *Perm J*. 2016;20(3):15-080.
136. Schroeder EB, Karter AJ. Brief Commentary: Glycemic Targets for Older Adults With Type 2 Diabetes. *Ann Intern Med*. 2018;169(4):250-251.
137. Weiner JZ, Gopalan A, Mishra P, et al. Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes. *JAMA Intern Med*. 2019;179(12):1633-1641.
138. McCormick TA, Adams JL, Lee EA, et al. Age-Dependent Hemoglobin A1c Therapeutic Targets Reduce Diabetic Medication Changes in the Elderly. *EGEMS (Wash DC)*. 2019;7(1):46.
139. Parker MM, Fernández A, Moffet HH, et al. Association of Patient-Physician Language Concordance and Glycemic Control for Limited-English Proficiency Latinos With Type 2 Diabetes. *JAMA Intern Med*. 2017;177(3):380-387.
140. Karter AJ, Parker MM, Moffet HH, et al. Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 Diabetes. *Diabetes Technol Ther*. 2022;24(5):332-337.
141. Karter AJ, Parker MM, Moffet HH, et al. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. *JAMA*. 2021;325(22):2273-2284.
142. Bailey SR, O'Malley JP, Gold R, et al. Receipt of Diabetes Preventive Services Differs by Insurance Status at Visit. *Am J Prev Med*. 2015;48(2):229-233.
143. Gold R, McIntire PJ, Puro JE, et al. Receipt of diabetes preventive care among safety net patients associated with differing levels of insurance coverage. *J Am Board Fam Med*. 2012;25(1):42-49.
144. Hudson SM, Modjtahedi BS, Altman D, et al. Factors Affecting Compliance with Diabetic Retinopathy Screening: A Qualitative Study Comparing English and Spanish Speakers. *Clin Ophthalmol*. 2022;16:1009-1018.
145. An J, Niu F, Turpcu A, et al. Adherence to the American Diabetes Association retinal screening guidelines for population with diabetes in the United States. *Ophthalmic Epidemiol*. 2018;25(3):257-265.
146. Ratanawongsa N, Crosson JC, Schillinger D, et al. Getting Under the Skin of Clinical Inertia in Insulin Initiation: The Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. *Diabetes Educ*. 2012;38(1):94-100.
147. Schmittiel JA, Raebel MA, Dyer W, et al. Prescription medication burden in patients with newly diagnosed diabetes: A SURveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. *J Am Pharm Assoc (2003)*. 2014;54(4):374-382.
148. Schwartz DD, Stewart SD, Aikens JE, et al. Seeing the Person, Not the Illness: Promoting Diabetes Medication Adherence Through Patient-Centered Collaboration. *Clin Diabetes*. 2017;35(1):35-42.
149. Adams AL, Paxton EW, Wang JQ, et al. Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001 to 2009. *J Bone Joint Surg Am*. 2013;95(6):481-487.
150. Sagray BA, Malhotra S, Steinberg JS. Current therapies for diabetic foot infections and osteomyelitis. *Clin Podiatr Med Surg*. 2014;31(1):57-70.
151. Akhabue E, Rittner SS, Carroll JE, et al. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers. *J Am Heart Assoc*. 2017;6(7):e005627.

152. Marcum ZA, Forsberg CW, Moore KP, et al. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease. *J Gen Intern Med.* 2018;33(2):155-165.
153. Nichols GA, Philip S, Reynolds K, et al. Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol. *Diabetes Obes Metab.* 2019;21(2):366-371.
154. Fitzpatrick SL, Hill-Briggs F. Strategies for Sustained Weight Management: Perspectives From African American Patients With Type 2 Diabetes. *Diabetes Educ.* 2017;43(3):304-310.
155. Rana JS, Karter AJ, Liu JY, et al. Improved Cardiovascular Risk Factors Control Associated with a Large-Scale Population Management Program Among Diabetes Patients. *Am J Med.* 2018;131(6):661-668.
156. Schmittiel JA, Adams SR, Goler N, et al. The impact of telephonic wellness coaching on weight loss: A "Natural Experiments for Translation in Diabetes (NEXT-D)" study. *Obesity (Silver Spring).* 2017;25(2):352-356.
157. Schmittiel JA, Brown SD, Neugebauer R, et al. Health-Plan and Employer-Based Wellness Programs to Reduce Diabetes Risk: The Kaiser Permanente Northern California NEXT-D Study. *Prev Chronic Dis.* 2013;10:E15.
158. Rossom RC, Solberg LI, Magnan S, et al. Impact of a national collaborative care initiative for patients with depression and diabetes or cardiovascular disease. *Gen Hosp Psychiatry.* 2017;44:77-85.
159. Coleman KJ, Magnan S, Neely C, et al. The COMPASS initiative: description of a nationwide collaborative approach to the care of patients with depression and diabetes and/or cardiovascular disease. *Gen Hosp Psychiatry.* 2017;44:69-76.
160. Chwastiak LA, Jackson SL, Russo J, et al. A collaborative care team to integrate behavioral health care and treatment of poorly-controlled type 2 diabetes in an urban safety net primary care clinic. *Gen Hosp Psychiatry.* 2017;44:10-15.
161. Coleman KJ, Hemmila T, Valenti MD, et al. Understanding the experience of care managers and relationship with patient outcomes: the COMPASS initiative. *Gen Hosp Psychiatry.* 2017;44:86-90.
162. Beck A, Boggs JM, Alem A, et al. Large-Scale Implementation of Collaborative Care Management for Depression and Diabetes and/or Cardiovascular Disease. *J Am Board Fam Med.* 2018;31(5):702-711.
163. Benedict AW, Spence MM, Sie JL, et al. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System. *J Manag Care Spec Pharm.* 2018;24(2):114-122.
164. Adams SR, Wiley DM, Fargeix A, et al. Employer-Based Screening for Diabetes and Prediabetes in an Integrated Health Care Delivery System: A Natural Experiment for Translation in Diabetes (NEXT-D) Study. *J Occup Environ Med.* 2015;57(11):1147-1153.
165. Melles RB, Conell C, Siegner SW, Tarasewicz D. Diabetic retinopathy screening using a virtual reading center. *Acta Diabetol.* 2020;57(2):183-188.
166. Schmittiel JA, Marshall CJ, Wiley D, et al. Opportunities to encourage mail order pharmacy delivery service use for diabetes prescriptions: a qualitative study. *BMC Health Serv Res.* 2019;19(1):422.
167. Ramachandran B, Trinacty CM, Wharam JF, et al. A Randomized Encouragement Trial to Increase Mail Order Pharmacy Use and Medication Adherence in Patients with Diabetes. *J Gen Intern Med.* 2021;36(1):154-161.
168. Ferrara A, Hedderson MM, Ching J, et al. Referral to telephonic nurse management improves outcomes in women with gestational diabetes. *Am J Obstet Gynecol.* 2012;206(6):491.e491-495.
169. Brown SD, Grijalva CS, Ferrara A. Leveraging EHRs for patient engagement: perspectives on tailored program outreach. *Am J Manag Care.* 2017;23(7):e223-e230.
170. Graetz I, Huang J, Brand RJ, et al. Bridging the digital divide: mobile access to personal health records among patients with diabetes. *Am J Manag Care.* 2018;24(1):43-48.
171. Graetz I, Huang J, Muelly ER, et al. Association of Mobile Patient Portal Access With Diabetes Medication Adherence and Glycemic Levels Among Adults With Diabetes. *JAMA Netw Open.* 2020;3(2):e1921429.
172. Karter AJ, Warton EM, Lipska KJ, et al. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. *JAMA Intern Med.* 2017;177(10):1461-1470.
173. Parker MM, Moffet HH, Adams A, Karter AJ. An algorithm to identify medication nonpersistence using electronic pharmacy databases. *J Am Med Inform Assoc.* 2015;22(5):957-961.
174. Reed M, Huang J, Graetz I, et al. Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus. *Ann Intern Med.* 2012;157(7):482-489.
175. Richardson MJ, Van Den Eeden SK, Roberts E, et al. Evaluating the Use of Electronic Health Records for Type 2 Diabetes Surveillance in 2 California Counties, 2010-2014. *Public Health Rep.* 2017;132(4):463-470.
176. Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA. Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. *Pharmacoepidemiol Drug Saf.* 2018;27(10):1053-1059.



177. Schroeder EB, Xu S, Goodrich GK, et al. Predicting the 6-month risk of severe hypoglycemia among adults with diabetes: Development and external validation of a prediction model. *J Diabetes Complicat.* 2017;31(7):1158-1163.
178. Graetz I, Huang J, Brand R, et al. Mobile-accessible personal health records increase the frequency and timeliness of PHR use for patients with diabetes. *J Am Med Inform Assoc.* 2019;26(1):50-54.
179. Reed M, Huang J, Brand R, et al. Implementation of an outpatient electronic health record and emergency department visits, hospitalizations, and office visits among patients with diabetes. *JAMA.* 2013;310(10):1060-1065.
180. Tarasewicz D, Karter AJ, Pimentel N, et al. Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm. *Diabetes Care.* 2023;46(5):1068-1075.
181. Harrison TN, Sacks DA, Parry C, et al. Acceptability of Virtual Prenatal Visits for Women with Gestational Diabetes. *Womens Health Issues.* 2017;27(3):351-355.
182. Xiao H, Adams SR, Goler N, et al. Wellness Coaching for People With Prediabetes: A Randomized Encouragement Trial to Evaluate Outreach Methods at Kaiser Permanente, Northern California, 2013. *Prev Chronic Dis.* 2015;12:E207.
183. Glasgow RE, Kurz D, Dickman JM, et al. Linking internet-based diabetes self-management to primary care: lessons learned and implications for research translation and practice implementation. *Transl Behav Med.* 2012;2(3):313-321.
184. Force USPST, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2018;320(11):1163-1171.
185. Grant RW, Gopalan A, Jaffe MG. Updated USPSTF Screening Recommendations for Diabetes: Identification of Abnormal Glucose Metabolism in Younger Adults. *JAMA Intern Med.* 2021;181(10):1284-1286.
186. Jonas DE, Vander Schaaf EB, Riley S, et al. Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2022;328(10):968-979.
187. Garber AJ, Abrahamson MJ, Barzilay JI, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. *Endocr Pract.* 2016;22(1):84-113.
188. Garber AJ, Abrahamson MJ, Barzilay JI, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. *Endocr Pract.* 2018;24(1):91-120.
189. Garber AJ, Abrahamson MJ, Barzilay JI, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. *Endocr Pract.* 2017;23(2):207-238.
190. Garber AJ, Handelsman Y, Grunberger G, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. *Endocr Pract.* 2020;26(1):107-139.
191. Wexler DJ, Powe CE, Barbour LA, et al. Research Gaps in Gestational Diabetes Mellitus: Executive Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. *Obstet Gynecol.* 2018;132(2):496-505.
192. Health Care Systems Research Network. Who We Are. 2015; <http://www.hcsrn.org/en/About/>. Accessed January 22, 2018.
193. \$5.6 million awarded to Kaiser Permanente researcher to study treatments for type 2 diabetes [press release]. March 18, 2021 2021.
194. DiCAYA Network. Welcome to DiCAYA Network. 2023; <https://www.dicaya.org/>. Accessed September 15, 2023.